These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 22858089)

  • 1. [Analysis of adherence and efficiency when replacing an antiretroviral therapy with efavirenz-emtricitabine-tenofovir in a single daily dose].
    García-Ramos SE; Santolaya Perrín MR; Fernández-Pacheco García-Valdecasas M
    Farm Hosp; 2012; 36(5):315-20. PubMed ID: 22858089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efavirenz + emtricitabine + tenofovir: new combination. HIV infection: do not modify ongoing therapy just to use one less tablet. Better adherence than with separate dosing has not been demonstrated, while reduced efficacy is plausible.
    Prescrire Int; 2009 Jun; 18(101):105. PubMed ID: 19637416
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
    Sánchez-de la Rosa R; Herrera L; Moreno S
    Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [HIV therapy and adherence].
    Kuhlmann B
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():62-3. PubMed ID: 19024920
    [No Abstract]   [Full Text] [Related]  

  • 5. Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
    Semvua HH; Mtabho CM; Fillekes Q; van den Boogaard J; Kisonga RM; Mleoh L; Ndaro A; Kisanga ER; van der Ven A; Aarnoutse RE; Kibiki GS; Boeree MJ; Burger DM
    Antivir Ther; 2013; 18(1):105-13. PubMed ID: 23043067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New once-daily HIV combination better tolerated.
    Expert Rev Anti Infect Ther; 2004 Dec; 2(6):826. PubMed ID: 15566325
    [No Abstract]   [Full Text] [Related]  

  • 7. Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: a large cross-sectional study of HIV-infected patients on antiretroviral therapy.
    Gianotti N; Galli L; Bocchiola B; Cahua T; Panzini P; Zandonà D; Salpietro S; Maillard M; Danise A; Pazzi A; Lazzarin A; Castagna A
    HIV Med; 2013 Mar; 14(3):153-60. PubMed ID: 22994659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination tablet.
    Frampton JE; Croom KF
    Drugs; 2006; 66(11):1501-12; discussion 1513-4. PubMed ID: 16906786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent FDA approvals and changes.
    AIDS Patient Care STDS; 2010 Feb; 24(2):133-4. PubMed ID: 20156092
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and efficacy of tenofovir/emtricitabine or abacavir/lamivudine in combination with efavirenz in treatment naïve HIV patients: a 5 year retrospective observational cohort study. (the TOKEN Study).
    Pammi M; Arumainayagam J; Kumari B; Ahmed-Jushuf I; Carlin EM; Chandramani S; Riddell L; Ghanem M; Das S
    Int J Clin Pract; 2013 Sep; 67(9):922-3. PubMed ID: 23952469
    [No Abstract]   [Full Text] [Related]  

  • 11. [One year with Atripla. Changeover to complete HIV therapy in a single tablet has proven successful].
    Warpakowski A
    MMW Fortschr Med; 2009 Apr; 151(18):54-5. PubMed ID: 19769077
    [No Abstract]   [Full Text] [Related]  

  • 12. Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment.
    Olin JL; Spooner LM; Klibanov OM
    Ann Pharmacother; 2012 Dec; 46(12):1671-7. PubMed ID: 23136357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.
    Bickel M; Bodtländer A; Knecht GK; Stephan C; von Hentig N; Kurowski M; Gute P; Klauke S; Lutz T
    J Antimicrob Chemother; 2009 Dec; 64(6):1260-4. PubMed ID: 19776037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First of a kind in HIV treatment.
    FDA Consum; 2006; 40(6):34. PubMed ID: 17333565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.
    Martin A; Bloch M; Amin J; Baker D; Cooper DA; Emery S; Carr A
    Clin Infect Dis; 2009 Nov; 49(10):1591-601. PubMed ID: 19842973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiretroviral rounds. Is that "one pill" treatment enough?
    Gallant JE; Arribas JR
    AIDS Clin Care; 2008 Jul; 20(7):53-4. PubMed ID: 18724479
    [No Abstract]   [Full Text] [Related]  

  • 17. Tenofovir/emtricitabine/efavirenz plus rosuvastatin decrease serum levels of inflammatory markers more than antiretroviral drugs alone in antiretroviral therapy-naive HIV-infected patients.
    Calza L; Vanino E; Salvadori C; Manfredi R; Colangeli V; Cascavilla A; Di Bari MA; Motta R; Viale P
    HIV Clin Trials; 2014; 15(1):1-13. PubMed ID: 24518210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Budget impact of a set-dose combination of efavirenz-emtricitabine-tenofovir in the treatment of patients infected with HIV-1].
    Oyagüez I; Casado MA; Cotarelo M; Ramírez-Arellano A; Mallolas J
    Farm Hosp; 2009; 33(5):247-56. PubMed ID: 19775575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [One pill--all HAART. Complete divergent HAART in a single tablet per day].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():76-7. PubMed ID: 19024926
    [No Abstract]   [Full Text] [Related]  

  • 20. [Complete HAART in a single pill. New milestone for improving compliance].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():40-1. PubMed ID: 19024916
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.